Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PhaseⅠ-Ⅱ Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF(PraG) With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors

NCT05435768 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT05435768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PhaseⅠ-Ⅱ Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF(PraG) With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors
Lead sponsor
Second Affiliated Hospital of Soochow University
Phase
Observational
Overall status
Unknown status
Start date
August 16, 2022
Completion date
August 15, 2025
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumor